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Abstract
Medical gas research often involves the study of molecules under extraphysiologic conditions, that is, conditions
that do not exist in nature. This “supernatural” nature of medical gas research sometimes produces results that
appear to be almost “magic” to those schooled in traditional physiology
“Any sufficiently advanced technology is indistinguishable from magic”.
-Arthur C. Clarke
Often times in the day to day work of scientific endeavor,
our efforts are not so much discovery as window dres-
sing. Innovation has become a casualty of increasingly
limited resources and the demands for concrete results in
return for investment. Thus, the National Institutes of
Health (NIH) tend to fund known investigators in estab-
lished project lines and we learn more and more about
vanishingly small and irrelevant details of things such as
the thromboelastographic characterization of fibrinolysis,
while the incidence of autism in the United States stands
at 1 in 110 children and continues to increase without
explanation [1]. Similarly, commercial scientific funding
emphasizes the certain result, that is, the “win”,r a t h e r
than a gamble on the unknown and studies of Pharma
drug × vs. drug Y predominate, but studies of drug × on
an untested medical condition are far less common, that
is, nonexistent. Even in the Food and Drug Administra-
tion (FDA), hallmark terms are “non-inferior” and “sub-
stantially equivalent”, with the path for approval of the
unique product in an unmet area of therapeutic need is
extraordinarily arduous, to the point of killing new tech-
nologies before they are born.
In a sense, scientific innovation has been the victim of
the expansion of our body of knowledge. In an earlier
era, all investigation broke new ground and any research
could be considered “high risk”,a st h e r ew a sn oa s s u r -
ance of a useful result. So, we have reached a point where
we understand just enough about the known universe to
limit the exploration of new territory. After all, if we are
comfortable in our neighborhood, why go traveling
across town to unfamiliar areas? Indeed, basic research
has become so arcane that we have developed a new
term, “translational”, to emphasize the practical applica-
tion of these arcane findings. We find this to be a curious
sort of lexography; after all, if research is truly relevant,
does it need translation? In our quest for the “sure thing”
we struggle to find meaning for the meaningless. One
need look only to the expansion of medical knowledge in
the decade 1960-1970 compared to 2000-2010 as a
demonstration of where we are (not) going. Could an
innovation such as cardiopulmonary bypass be fostered
in the contemporary era and is it any wonder that the
delineation of the human genome has yielded little tangi-
ble result?
Hyperbaric oxygen (HBO) is one of these “frontier”
therapies that, despite showing clinical promise, is widely
discounted except for a very small and limited set of indi-
cations (e.g. decompression illness, carbon monoxide poi-
soning), without evidence justifying the negative view of
the medical community, (including the Undersea and
Hyperbaric Medical Society, which is loathe to consider
applications of HBO outside of 13 “approved indications)
[2]. Many otherwise reasonable clinicians and scientists
automatically dismiss any usefulness of HBO for “off-
label” conditions, such as stroke, concussion and autism,
even when presented with well-conducted studies
demonstrating effectiveness. Much of this has to do with
the “supernatural” nature of oxygen under pressure and
remarkable results that appear as “magic” to those versed
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HBO is not the stuff of ghosts and goblins, but rather,
the behavior of a natural substance under extraphysiolo-
gic conditions. Normal human physiology takes place at
or near normal atmospheric pressure, so the behavior of
a familiar molecule, such as oxygen, under “supernatural”
conditions is not only unpredictable, but also potentially
efficacious in completely unexpected ways. Clinically,
HBO appears to offer benefit in multiple neurologic con-
ditions including autism, stroke and concussion [3,4].
Some results, such as the amelioration of neonatal
asphyxia with one rescue treatment [5], are so unex-
pected that they appear to be magic. HBO is not magic; it
is simply the behavior of a molecule in a mileu outside of
human experience. Recall that the physiology of many
organisms at extremes of temperature and pressure, such
as deep-dwelling sea creatures, appeared initially to be
strange and unusual “magic”.
All of this would be fodder for quiet academic fireside
discussion, were it not for the very real patients whose
suffering could be helped by a treatment, HBO, that is
ignored because of its foreign and unexpected results.
After all, we were taught in medical school that neurolo-
gic damage is permanent, brain cells do not lay dormant
and they certainly do not regenerate and yet, all of these
axioms have been found to be untrue, but sometimes
under unusual, “supernatural” conditions. Sports fans
may be familiar with Dave Duerson. A formidable defen-
sive player, Duerson was widely acclaimed for his ability
to deliver devastating blows and sack quarterbacks.
Unsuccessful following his professional career, he com-
mitted suicide earlier this year and asked that his brain
be examined for damage sustained as a result of concus-
sions sustained throughout his career. Duerson was
indeed found to have chronic traumatic encephalopathy
(CTE) that may have caused his depression and cognitive
dysfunction. It is the clinical impression of physicians
using HBO that the therapy is extraordinarily effective
for CTE and has benefited many who have the means to
find and fund the therapy (personal communication, Pete
Stephens, MD). These physicians are greatly frustrated
and become emotional at the thought of the suffering
that could be eliminated and the natural history of CTE
changed, were the therapy accepted and reimbursed by
third party payers, such as Medicare. At our institution,
we have started an observational study of the effective-
ness of HBO in CTE, including a search for objective bio-
markers, but skepticism of the “supernatural” effects of
HBO dictates that it will be quite some time before this
therapy becomes “standard of care”. Similarly, HBO is
showing clinical promise in the treatment of autism [4],
but is widely considered to be just slightly above quack-
ery. Again, we are taught that autism is a condition that
has to be managed and cannot be treated. At Drexel we
have also started down that long road to “standard of
care” and evaluating the role of HBO in autism, using
investigational biomarkers. Parents and caregivers, how-
ever, know and see the remarkable improvement in some
autistic children following HBO treatment and do not
care to wait for the scientific establishment to pronounce
the therapy validated. Without the validation, unfortu-
nately, the therapy is not reimbursed and the promise of
a better way of life for their children is limited to those
able to shoulder the expense.
Finally, our veneration of the established limits our abil-
ity to discard the “proven” technologies in use, even when
they present a hazard to health and safety. The volatile
anesthetic gases are an example. Sevoflurane is the most
commonly used volatile anesthetic gas, especially in pedia-
tric anesthesia, where it has nearly 100% of the market. It
enjoys the advantages of pleasant smell, ease of use, cardi-
ovascular stability and relatively low blood solubility.
Previous to its introduction in 1992, pediatric anesthesia
was dominated by halothane, which was troubled by a
propensity for cardiac arrhythmias, increased incidence of
hepatitis and high blood solubility leading to prolonged
time to emerge from anesthesia. It is not surprising, there-
fore, that, once introduced, sevoflurane quickly replaced
halothane. Unfortunately, that is not the end of the story.
Recent animal studies have conclusively demonstrated
that all the NMDA receptor antagonists, including sevo-
flurane, cause widespread neurodegeneration and brain
damage in infants [6,7]. In our laboratories, we are evaluat-
ing the influence of anesthetic exposure in a developing
drosophila, that is, fruit fly model. Initially, it appears that
flies exposed to sevoflurane become “forgetful”, mimicking
the behavior of flies that have been genetically modified to
express proteins found in human Alzheimer’s disease
(unpublished data). Normal fruit flies climb the walls of a
glass jar when inverted; “forgetful” fruit flies do not. Addi-
tionally, there is some clinical evidence that sevoflurane is
associated with a higher incidence of postoperative delir-
ium, seizures and prolonged cognitive dysfunction in
h u m a n s[ 8 - 1 0 ] .M o r ew o r r i s o m e ,t h e r ea r es o m es t u d i e s
in both animals and humans suggesting that exposure to
anesthetics at an early age correlates with a diagnosis of
neurodevelopmental diseases later in life, including learn-
ing disabilities and autism [7,11]. This is not a mystery to
the FDA and has been the subject of two review panels.
Alternative anesthetics that seem to be less neurotoxic,
such as desflurane and propofol, are available and safe
in children, but they are more technically difficult to
administer. So, despite this accumulation of “soft” evi-
dence, there is an unwillingness to abandon sevoflurane,
leading the FDA to make the confusing recommendation
that, while there is not enough evidence to recommend a
change in the existing practice of sevoflurane use, anesthe-
s i as h o u l db ea v o i d e di nc h i l d r e nu n d e ra g e2[ 1 2 ] .T h e
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of sevoflurane, while the incidence of autism in the United
States has continually increased without explanation since
1992, the year of sevoflurane’s introduction to the market.
Coincidence? Possbily. Statistics are funny things and,
given a large enough database, the incidence of autism can
probably be shown to correlate with the incidence of elec-
tric car use in California. So this may all be a statistical
accident and the correlation meaningless. Absence of evi-
dence, however, is not evidence of absence and it is also
possible that sevoflurane is the thalidomide of the new
millennium. Our laboratories are not only further examin-
ing the statistical correlations, we are also investigating the
role of HBO in the prevention and treatment of anes-
thetic-induced neurodegeneration.
We therefore welcome with great excitement and enthu-
siasm the Journal of Medical Gas Research. As we have
discussed, medical gases, such as HBO and sevoflurane,
can manifest unusual and unexpected behavior at the
molecular level. The atmospheric “phlogiston” of the pre-
scientific era may still excite as we examine the unknown,
the “magic” behavior of the natural under “supernatural”
conditions. There is no more thrilling feeling than to
experience a completely unexpected and unexplainable
result of a scientific study. In medical gas research, we are
all pioneers of a sort and we congratulate the readership
of the new journal on joining in our adventure. Those
who wish to closely examine the 15
th variation of the 22
nd
step of fibrinolysis may be best served at another venue.
Those who want to experience at least some portion of
the feeling that Neil Armstrong had with that “one small
step”, need only read on.
Philadelphia, PA
June, 2011
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